VIRIOS THERAPEUTICS INC (VIRI) Stock Price & Overview
NASDAQ:VIRI • US92829J1043
Current stock price
The current stock price of VIRI is 0.155 USD. Today VIRI is up by 12.4%. In the past month the price decreased by -11.68%. In the past year, price decreased by -80.5%.
VIRI Key Statistics
- Market Cap
- 172.05K
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.24
- Dividend Yield
- N/A
VIRI Stock Performance
VIRI Stock Chart
VIRI Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to VIRI. When comparing the yearly performance of all stocks, VIRI is a bad performer in the overall market: 97.01% of all stocks are doing better.
VIRI Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to VIRI. The financial health of VIRI is average, but there are quite some concerns on its profitability.
VIRI Earnings
VIRI Forecast & Estimates
8 analysts have analysed VIRI and the average price target is 1.43 USD. This implies a price increase of 821.29% is expected in the next year compared to the current price of 0.155.
VIRI Groups
Sector & Classification
VIRI Financial Highlights
Over the last trailing twelve months VIRI reported a non-GAAP Earnings per Share(EPS) of -0.24. The EPS increased by 56.36% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -145.66% | ||
| ROE | -168.89% | ||
| Debt/Equity | 0 |
VIRI Ownership
VIRI Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.63 | 376.832B | ||
| AMGN | AMGEN INC | 15.41 | 188.135B | ||
| GILD | GILEAD SCIENCES INC | 15.72 | 169.255B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.05 | 112.576B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.47 | 79.215B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 44.35 | 41.92B | ||
| INSM | INSMED INC | N/A | 33.048B | ||
| BIIB | BIOGEN INC | 11.35 | 27.528B | ||
| NTRA | NATERA INC | N/A | 26.481B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.68 | 25.788B | ||
| MRNA | MODERNA INC | N/A | 19.048B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 18.372B | ||
| INCY | INCYTE CORP | 12.23 | 17.977B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About VIRI
Company Profile
Virios Therapeutics, Inc. engages in pharmaceutical products for fibromyalgia and other related conditions. The company is headquartered in Alpharetta, Georgia. The company went IPO on 2020-12-17. The firm is focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response such as fibromyalgia (FM) and Long-COVID (LC). Its lead candidate, IMC-1, is a novel, proprietary, fixed dose combination of famciclovir and celecoxib. IMC-1 represents a novel combination, dual mechanism antiviral therapy designed to synergistically suppress herpes virus activation and replication, with the end goal of reducing viral mediated disease burden. IMC-2 is a combination of valacyclovir and celecoxib that is believed to have specific activity against Epstein-Barr virus (herpesvirus HHV-4), as well as other herpesviruses. IMC-1 and IMC-2 combine two specific mechanisms of action purposely designed to inhibit herpesvirus activation and replication, thereby converting activated herpesvirus back to dormancy and/or by keeping the herpesvirus in a latent or dormant state.
Company Info
IPO: 2020-12-17
VIRIOS THERAPEUTICS INC
44 Milton Avenue
Alpharetta GEORGIA US
Employees: 4
Phone: 18666208655
VIRIOS THERAPEUTICS INC / VIRI FAQ
What does VIRI do?
Virios Therapeutics, Inc. engages in pharmaceutical products for fibromyalgia and other related conditions. The company is headquartered in Alpharetta, Georgia. The company went IPO on 2020-12-17. The firm is focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response such as fibromyalgia (FM) and Long-COVID (LC). Its lead candidate, IMC-1, is a novel, proprietary, fixed dose combination of famciclovir and celecoxib. IMC-1 represents a novel combination, dual mechanism antiviral therapy designed to synergistically suppress herpes virus activation and replication, with the end goal of reducing viral mediated disease burden. IMC-2 is a combination of valacyclovir and celecoxib that is believed to have specific activity against Epstein-Barr virus (herpesvirus HHV-4), as well as other herpesviruses. IMC-1 and IMC-2 combine two specific mechanisms of action purposely designed to inhibit herpesvirus activation and replication, thereby converting activated herpesvirus back to dormancy and/or by keeping the herpesvirus in a latent or dormant state.
What is the stock price of VIRIOS THERAPEUTICS INC today?
The current stock price of VIRI is 0.155 USD. The price increased by 12.4% in the last trading session.
Does VIRI stock pay dividends?
VIRI does not pay a dividend.
What is the ChartMill technical and fundamental rating of VIRI stock?
VIRI has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Should I buy VIRI stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on VIRI.
Can you provide the upcoming earnings date for VIRIOS THERAPEUTICS INC?
VIRIOS THERAPEUTICS INC (VIRI) will report earnings on 2024-11-11, before the market open.